2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

602. Myeloid Oncogenesis: Basic

Program: Oral Abstract Session
Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - R06-R09
Technology and Procedures, Imaging, Omics Technologies, Computational Biology, Gene Editing, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Study Population, Human, Animal Model
PAPER

215 Modeling AML by sequential sub-stoichiometric mutagenesis in native haematopoiesis

Rabea Mecklenbrauck, MD, Zishan Zhang2, Susann Rahmig3, Jackie Sloane-Stanley4, Camelia Benlabiod, PhD5, Alexandre Fagnan, PhD6, Clement Hallou7, Anouck De Rooij8, Philip Hublitz9, Bethan Psaila, Md PhD10, Christian Babbs11, Paresh Vyas, MD, PhD12, Claus Nerlov, PhD13
1 MRC Weatherall Institute of Molecular Medicine, Oxford, United Kingdom
2 MRC Weatherall Institute of Molecular Medicine, Oxford, United Kingdom
3 MRC Weatherall Institute of Molecular Medicine, Oxford, United Kingdom
4 MRC Weatherall Institute of Molecular Medicine, Oxford, United Kingdom
5 MRC Weatherall Institute of Molecular Medicine, Oxford, United Kingdom
6 MRC Weatherall Institute of Molecular Medicine, Oxford, United Kingdom
7 MRC Weatherall Institute of Molecular Medicine, Oxford, United Kingdom
8 MRC Weatherall Institute of Molecular Medicine, Oxford, United Kingdom
9 MRC Weatherall Institute of Molecular Medicine, Oxford, United Kingdom
10 MRC Weatherall Institute of Molecular Medicine, Oxford, United Kingdom
11 MRC Weatherall Institute of Molecular Medicine, Oxford, United Kingdom
12 MRC Weatherall Institute of Molecular Medicine, Oxford, United Kingdom
13 MRC Weatherall Institute of Molecular Medicine, Oxford, United Kingdom

Background: Hematologic malignancies arise through sequential acquisition of mutations within evolving clones. Mutation order, premalignant clone size, and competition with normal hematopoiesis may shape transformation, but these variables are challenging to model in native hematopoiesis. Conventional conditional mouse models usually induce mutations in most, or all target cells, not enabling study of mutant-wild-type competition. Viral transduction and transplantation introduce an artificial selective bottleneck and express oncogenes at non-physiological levels. To model clonal evolution in leukemogenesis more faithfully, we developed a platform for stochastic, low-frequency, sequential induction of disease-associated mutations in unperturbed hematopoiesis.

Methods: Competition between heterotypic LoxP and Loxm2 sites was used to stochastically activate a cassette encoding a tdTomato, FlpO, and tamoxifen (Tam)-inducible DreERT2 in the Rosa26 locus in a subset of cells. By mutating the Loxm2 sites, we generated three Lox-STOP-FlpO-Dre (LSFD) alleles designed to recombine Loxm2 sites and express the cassette in approximately 20% (LSFD1), 1% (LSFD3), or 0.1% of cells (LSFD4) after Cre induction. Mice carrying LSFD1, poly(IC)-inducible Mx1-Cre and a Dre-Flp-Cre-conditional EGFP reporter (RC::RFLTG) were poly(IC) and Tam-treated to confirm Dre and Flp activation by Cre. LSFD alleles and Mx1-Cre were also combined with Flp-conditional Tet2 and Dre-conditional Npm1cA and Flt3-ITD alleles, and poly(IC) and subsequently Tam-treated to sequentially introduce mutations. Recombination and hematopoietic output were monitored by flow cytometry, variant allele frequencies (VAFs) were quantified by ddPCR, and leukemia phenotype and survival were assessed.

Results: The three LSFD alleles reproducibly generated approximately 20%, 1%, and 0.1% tdTomato-expressing cells across all blood lineages after Cre activation from the primitive LSK fraction to all mature cells, establishing distinct levels of somatic mosaicism that were stable for >4 months, consistent with recombination in hematopoietic stem cells (HSCs). Accordingly, in mice carrying RC::RFLTG, EGFP-positive cells were detected after LSFD1 induction by Mx1-Cre and Dre activation by tamoxifen across HSC, progenitor and mature compartments, confirming Flp- and Dre-mediated recombination throughout the blood system in vivo.

Dre-mediated induction of Npm1cA and Flt3-ITD produced rapid-onset acute leukemia from all LSFD alleles. Leukemia onset was significantly delayed in the 0.1% group compared with the 20% and 1% groups, where there was no difference; median overall survival was 50, 48, and 67 days respectively (p = 0.005 between 0.1% and 20%, p = 0.01 between 0.1% and 1%, p = 0.95% between 20% and 1%). This is consistent with a threshold below which mutant population size becomes rate-limiting for transformation. Phenotypically, the leukemia was uniformly myeloid (CD11b and Ly6C expression). ddPCR confirmed Npm1cA and Flt3-ITD. Flt3-ITD loss-of-heterozygosity was often seen, consistent with selection and genetic evolution during progression. Leukemias were transplantable and induced fatal disease in recipients with a median survival of 31 days.

To model stepwise leukemogenesis, we combined the Flp-conditional Tet2 allele with the Dre-conditional Npm1cA and Flt3-ITD alleles. ddPCR confirmed that Tet2 recombination could be induced independently of Npm1cA and Flt3-ITD recombination, enabling establishment of a sub-stoichiometric premalignant Tet2-mutant population, followed by introduction of leukemia-defining mutations in the same subpopulation. This strategy models progression from clonal hematopoiesis to overt leukemia while preserving an unperturbed environment.

Conclusion: This work provides a flexible genetic system for reproducible, stochastic, and sequential induction of mutations at defined sub-stoichiometric levels in unperturbed hematopoiesis. The model preserves competition between mutant and wild-type cells, reveals a mutant VAF-dependent leukemia latency, and captures clinically relevant clonal evolution, including Flt3-ITD loss-of-heterozygosity. Unlike transplantation-based systems, it permits longitudinal study of malignant evolution from its earliest stages in the native host. This platform provides a broadly adaptable approach to investigate clonal competition, mutation order, and stepwise transformation in blood cancers and potentially other tissues.

Rabea Mecklenbrauck, MD: No relevant conflicts of interest to declare.